Alex Depaoli Email Address

Chief Medical Officer and Vice President Translational Research

Founded in 2008, NGM is a privately-held drug discovery company committed to the identification and development of transformational biologics for diabetes, obesity, muscle wasting and other cardiometabolic diseases. The Company is focused on discovering the next generation of therapeutics that will fundamentally change the treatment paradigm for the growing population of cardiometabolic disease patients worldwide, and NGM's core assets enable us to deliver on that promise: High-throughput platform that can discover protein and peptide hormones, as well as other druggable targets with interesting physiological activity in the gastrointestinal (GI) tract and other metabolically-relevant tissues Integrated translational research and protein sciences capabilities to enable a program to seamlessly advance from discovery to clinical development Accomplished research and management team with deep drug discovery and protein sciences experience World-class advisors with expertise in metabolic diseases, bariatric surgery science and biologics drug discovery and development NGM has identified a rich pipeline of novel targets with profound metabolic effects in various animal models of diabetes, obesity and muscle wasting.

Dr. DePaoli has more than 20 years of experience in the diabetes, obesity and metabolic disease fields. He trained in Clinical and Molecular Endocrinology at the University of Chicago with Dr. Kenneth Polonski and in the Howard Hughes laboratory of Dr. Graham Bell. His clinical and research interests in diabetes and obesity were focused during his work at the Sansum Diabetes Research Institute with Dr. Lois Jovanovic, which led him to join Amgen in 1998 to develop their metabolic disease group. His work at Amgen was pivotal in enabling multiple clinical applications of the adipocytokine leptin. He has worked on a broad array of cardio-metabolic, muscle and bone disease targets with a focus on translating novel pathways into the clinic. These pathways include: 11 Beta HSD-1, Myostatin, RANK Ligand, IL-1 receptor, Calcium Sensing Receptor, PPAR-gamma modulation, DPP-4 and MCH-R1. Dr. DePaoli joined InteKrin Therapeutics in 2007 as Chief Medical Officer to develop a Selective PPAR-gamma Modulator. Dr DePaoli moved to NGM Biopharmaceuticals in April 2010 to head the Development organization. He also maintains a clinical endocrinology practice at the Sansum Diabetes Research Institute.